Hypoxic gene expression is a prognostic factor for disease free survival in a cohort of locally advanced squamous cell cancer of the uterine cervix

References

• Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86(8):1528–1536.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Overgaard J. The impact of hypoxia and its modification of the outcome of radiotherapy. J Radiat Res. 2016;57 (Suppl 1):i90–i98.
   PubMed Web of Science ®Google Scholar
• Nordsmark M, Loncaster J, Aquino-Parsons C, et al. The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol. 2006;80(2):123–131.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225–239.
   PubMed Web of Science ®Google Scholar
• Fjeldbo CS, Julin CH, Lando M, et al. Integrative analysis of DCE-MRI and gene expression profiles in construction of a gene classifier for assessment of hypoxia-related risk of chemoradiotherapy failure in cervical cancer. Clin Cancer Res. 2016;22(16):4067–4076.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25(26):4066–4074.
   PubMed Web of Science ®Google Scholar
• Pötter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021;22(4):538–547.
   PubMed Web of Science ®Google Scholar
• Schmid M, Mahantshetty U, Kirisits C, et al. Clinical characteristics and risk factors for local failure in cervix cancer patients after MR IGABT. Radiother Oncol. 2021;158(Suppl 1):S45.
   Google Scholar
• Dimopoulos JCA, Pötter R, Lang S, et al. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. Radiother Oncol. 2009;93(2):311–315.
   PubMed Web of Science ®Google Scholar
• Tanderup K, Fokdal LU, Sturdza A, et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiother Oncol. 2016;120(3):441–446.
   PubMed Web of Science ®Google Scholar
• Tan L-T, Pötter R, Sturdza A, et al. Change in patterns of failure after image-guided brachytherapy for cervical cancer: analysis from the RetroEMBRACE study. Int J Radiat Oncol Biol Phys. 2019;104(4):895–902.
   PubMed Web of Science ®Google Scholar
• Noordhuis MG, Eijsink JJH, Roossink F, et al. Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo) radiation: a systematic review. Int J Radiat Oncol Biol Phys. 2011;79(2):325–334.
   PubMed Web of Science ®Google Scholar
• Lyng H, Malinen E. Hypoxia in cervical cancer: from biology to imaging. Clin Transl Imaging. 2017;5(4):373–388.
   PubMed Web of Science ®Google Scholar
• Toustrup K, Sørensen BS, Metwally MAH, et al. Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials. Acta Oncol. 2016;55(9-10):1091–1098.
   PubMed Web of Science ®Google Scholar
• Toustrup K, Sørensen BS, Nordsmark M, et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 2011;71(17):5923–5931.
   PubMed Web of Science ®Google Scholar
• Toustrup K, Sørensen BS, Lassen P, et al. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol. 2012;102(1):122–129.
   PubMed Web of Science ®Google Scholar
• Hassan Metwally MA, Ali R, Kuddu M, et al. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma. Radiother Oncol. 2015;116(1):15–20.
   PubMed Web of Science ®Google Scholar
• Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 1998;46(2):135–146.
   PubMed Web of Science ®Google Scholar
• Lindegaard JC, Petric P, Lindegaard AM, et al. Evaluation of a new prognostic tumor score in locally advanced cervical cancer integrating clinical examination and magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2020;106(4):754–763.
   PubMed Web of Science ®Google Scholar
• Bentzen J, Toustrup K, Eriksen JG, et al. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Acta Oncol. 2015;54(7):1001–1007.
   PubMed Web of Science ®Google Scholar
• Saksø M, Mortensen LS, Primdahl H, et al. Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: long-term results from the DAHANCA 24 trial (NCT01017224). Radiother Oncol. 2020;151:126–133.
   PubMed Web of Science ®Google Scholar
• Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol. 2000;57(1):39–43.
   PubMed Web of Science ®Google Scholar
• Rose PG, Java J, Whitney CW, et al. Nomograms predicting progression-free survival, overall survival, and pelvic recurrence in locally advanced cervical cancer developed from an analysis of identifiable prognostic factors in patients from NRG oncology/gynecologic oncology group randomized trials of chemoradiotherapy . J Clin Oncol. 2015;33(19):2136–2142.
   PubMed Web of Science ®Google Scholar
• Lyng H, Sundfør K, Tropé C, et al. Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. Clin Cancer Res. 2000;6(3):1104–1112.
   PubMed Web of Science ®Google Scholar
• Mayr NA, Wang JZ, Zhang D, et al. Synergistic effects of hemoglobin and tumor perfusion on tumor control and survival in cervical cancer. Int J Radiat Oncol Biol Phys. 2009;74(5):1513–1521.
   PubMed Web of Science ®Google Scholar
• Lindegaard JC, Fokdal LU, Nielsen SK, et al. MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective. Acta Oncol. 2013;52(7):1510–1519.
   PubMed Web of Science ®Google Scholar
• Lindblom E, Dasu A, Beskow C, et al. High brachytherapy doses can counteract hypoxia in cervical cancer-a modelling study. Phys Med Biol. 2017;62(2):560–572.
   PubMed Web of Science ®Google Scholar
• Tanderup K, Nesvacil N, Kirchheiner K, et al. Evidence-based dose planning aims and dose prescription in image-guided brachytherapy combined with radiochemotherapy in locally advanced cervical cancer. Semin Radiat Oncol. 2020;30(4):311–327.
   PubMed Web of Science ®Google Scholar
• Lindegaard JC, Petric P, Schmid MP, et al. Tumor regression of cervical cancer during chemoradiation evaluated by the T-score in EMBRACE I. Radiother Oncol. 2021;158(Suppl 1):S16–S18.
   Google Scholar
• Mayr NA, Wang JZ, Zhang D, et al. Longitudinal changes in tumor perfusion pattern during the radiation therapy course and its clinical impact in cervical cancer. Int J Radiat Oncol Biol Phys. 2010;77(2):502–508.
   PubMed Web of Science ®Google Scholar
• Rofstad EK, Sundfør K, Lyng H, et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer. 2000;83(3):354–359.
   PubMed Web of Science ®Google Scholar
• Cibula D, Pötter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer. 2018;28(4):641–655.
   PubMed Web of Science ®Google Scholar
• Pötter R, Tanderup K, Kirisits C, et al. The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018;9:48–60.
   PubMed Web of Science ®Google Scholar
• Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-Year risk of cervical precancer and cancer in women with Human Papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072–1079.
   PubMedGoogle Scholar
• Burger RA, Monk BJ, Kurosaki T, et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst. 1996;88(19):1361–1368.
   PubMedGoogle Scholar
• Schwartz SM, Daling JR, Shera KA, et al. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol. 2001;19(7):1906–1915.
   PubMed Web of Science ®Google Scholar
• Lei J, Ploner A, Lagheden C, et al. High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study. PLoS Med. 2018;15(10):e1002666.
   PubMed Web of Science ®Google Scholar
• Hang D, Jia M, Ma H, et al. Independent prognostic role of human papillomavirus genotype in cervical cancer. BMC Infect Dis. 2017;17(1):391.
   PubMedGoogle Scholar